Presentation by Scott Harris, Chief Medical Officer, Altimmune, USA

Advancement in Therapeutics: Anti-Obesity Medications

Share this article:

Obesity is implicated in two-thirds of the leading causes of death from non-communicable diseases worldwide.

Obesity is implicated in two-thirds of the leading causes of death from non-communicable diseases worldwide. The global market size for medical weight loss is estimated to reach $54 billion by 2030. The co-morbidities of obesity include hypertension, type 2 diabetes melitus, coronary artery disease, osteoarthritis, sleep apnea, cancer, and NASH. The treatment of obesity is the cornerstone of treating NASH and the co-morbidities of NASH. The recent success of Wegovy ® (semaglutide 2.4 mg), a GLP-1 monotherapy, has created a regulatory pathway for incretin-based approaches. Numerous agents have been added to GLP-1 to achieve weight loss approaching bariatric surgery.